Impact of systemic therapies in metastatic melanoma of unknown primary: A study from MELBASE, a French multicentric prospective cohort

Perrine Rousset,Stéphane Dalle,Laurent Mortier,Olivier Dereure,Sophie Dalac,Caroline Dutriaux,Marie-Thérèse Leccia,Delphine Legoupil,Florence Brunet-Possenti,Julie De Quatrebarbes,Jean-Jacques Grob,Philippe Saiag,Eve Maubec,Pierre-Emmanuel Stoebner,Florence Granel-Brocard,Jean-Philippe Arnault,Clara Allayous,Bastien Oriano,Céleste Lebbe,Henri Montaudié

Journal of the American Academy of Dermatology（2023）

引用 1|浏览14

暂无评分

摘要

Although patients with MUP had less favorable baseline prognostic factors, they benefited from the novel therapies as much as those with cMKP. They should be managed according to similar strategies.

查看译文

关键词

advanced melanoma,adverse events,chemotherapy,immunotherapy,melanoma of known primary,melanoma of unknown primary,survival,systemic therapy,targeted therapy

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要